Amgen is sharing its latest advances in Thyroid Eye Disease at the European Thyroid Association's Annual Meeting.
Public source
Publisher name
Public post
Visits to multiple specialists. Years of waiting. And still, no clear diagnosis. For many people living with Thyroid Eye Disease (TED), the path to answers can be long a…
Company
Amgen
#WeareBiotech
- Industry
- Biotechnology Research
- Location
- Thousand Oaks, US
- Company size
- 10,001+ employees
About Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
See moreLatest activity
Latest activity from Amgen
42 signals
Research & Knowledge
Amgen announced that a global Phase 3 study evaluating its DLL3-targeting therapy as a first-line maintenance treatment for people with extensive-stage small cell lung cancer met its primary endpoint.
Research & Knowledge
Amgen published results from the GENERator team evaluating 12,026 oligonucleotides and finding regulatory elements beyond the natural comparison range.
Research & Knowledge
Amgen published results from the DISCO team screening 90 designed genes across four reactions and reporting up to 98 percent yield in one reaction.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
argenx
argenx represented colleagues from Medical Affairs, Clinical Development, and Patient Advocacy at the ETA2026 event in Porto to connect with the global thyroid community.
Presence & Recognition
Amgen Deutschland
Amgen Deutschland participated in the ESC Congress 2026 in Munich, Germany, focusing on topics such as lipids and cardiovascular prevention.
Presence & Recognition
Ascendis Pharma
Ascendis Pharma attended the International Skeletal Dysplasia Society Meeting in Toronto to participate in meaningful conversations with HCPs and industry partners.
Presence & Recognition
Tyra Biosciences
Tyra Biosciences traveled to Toronto for the International Skeletal Dysplasia Society 2026 Meeting to engage with the global skeletal dysplasia community and share updates on FGFR3 research.
Presence & Recognition
Genentech